Reinforcing and Discriminative Stimulus Effects of Ca-acetyl Homotaurine in Animals
Overview
Pharmacology
Psychology
Social Sciences
Authors
Affiliations
Ca-acetyl homotaurine (Ca-AOTA) has been proposed as an adjunct for ethanol detoxification. The purpose of the present experiment was to determine whether Ca-AOTA would be predicted to have abuse potential. Rhesus monkeys that were experienced in the intravenous self-administration of cocaine (n = 2) or pentobarbital (n = 2) were given the opportunity to self-administer various doses of Ca-AOTA or its vehicle (0.9% saline). Ca-AOTA (1.0-10.0 mg/kg/injection, intravenously) was not self-administered above saline levels. The discriminative stimulus effects of Ca-AOTA were evaluated in a drug discrimination procedure in which animals were trained to make one response after a training drug and a different response after saline. Rhesus monkeys trained to discriminate d-amphetamine (n = 3) or pentobarbital (n = 3) from saline were tested with doses of Ca-AOTA ranging from 10 to 100 mg/kg (PO by nasogastric tube) and at 3 different pretreatment times (1, 2, or 4 hr). Ca-AOTA failed to engender drug-appropriate responding at any dose or pretreatment condition in either group of monkeys. In addition, Ca-AOTA was tested in 4 pigeons trained to discriminate pentobarbital from saline. Ca-AOTA administration did not result in pentobarbital-appropriate responding in doses ranging from 30-300 mg/kg (IM) and pretreatment times ranging from 30 to 240 min. The lack of both reinforcing properties and discriminative stimulus properties similar to d-amphetamine or pentobarbital suggests that Ca-AOTA has little or no abuse potential.
Relapse Prevention in Alcoholism : Recent Advances and Future Possibilities.
Soyka M CNS Drugs. 2016; 7(4):313-27.
PMID: 27520754 DOI: 10.2165/00023210-199707040-00004.
Sinclair J, Chambers S, Shiles C, Baldwin D Drug Saf. 2016; 39(7):627-45.
PMID: 27023898 DOI: 10.1007/s40264-016-0416-y.
Safety and efficacy of acamprosate for the treatment of alcohol dependence.
Yahn S, Watterson L, Olive M Subst Abuse. 2013; 6:1-12.
PMID: 23399877 PMC: 3565569. DOI: 10.4137/SART.S9345.
The clinical pharmacology of acamprosate.
Kalk N, Lingford-Hughes A Br J Clin Pharmacol. 2013; 77(2):315-23.
PMID: 23278595 PMC: 4014018. DOI: 10.1111/bcp.12070.
Role of altered structure and function of NMDA receptors in development of alcohol dependence.
Nagy J, Kolok S, Boros A, Dezso P Curr Neuropharmacol. 2008; 3(4):281-97.
PMID: 18369402 PMC: 2268999. DOI: 10.2174/157015905774322499.